Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indicationMarch 19, 2026
Share Facebook Twitter LinkedIn Pinterest Email BlackRock successfully prices $3B offering of senior notes
Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indicationMarch 19, 2026